EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Efficacy of Ayurveda Regimen as an Adjunct to Hydroxyurea in Sickle Cell Disease: Protocol for a Prospective, Randomized, Open-Label, Blinded End Point Exploratory Study

Danish Javed iD, Amit Kumar Rai iD, Sachin Bansal iD, Babita Yadav iD, Manisha Shrivastava iD, Garima Goel iD, Ashok Kumar iD, Sanjeev Kumar iD, Azeem Ahmad iD, Richa Singhal iD, Bhagwan S Sharma iD, Anil Mangal iD und 3 weitere

JMIR Research Protocols · 2026

DOI: 10.2196/79603 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2026. Verfasst von Danish Javed und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy, All India Institute of Medical Sciences Bhopal, Room no 4, Ground floor…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hydroxyurea, Medicine, Ayurvedic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sickle cell disease (SCD) is a severe, inherited hemoglobin disorder characterized by chronic hemolysis, vaso-occlusive crises (VOCs), and systemic inflammation. Hydroxyurea is the standard conventional pharmacotherapy for SCD, but it has certain limitations, necessitating the need to explore other safe and effective treatment options for SCD. Ayurveda interventions offer a potential therapeutic approach complementary to conventional medicine for SCD management, with anti-inflammatory, immunomodulatory, and hematopoietic properties.

Objective

This randomized controlled trial will evaluate the efficacy and safety of an Ayurvedic therapeutic regimen as an adjunct to hydroxyurea in SCD management, assessing its impact on hematological parameters, inflammatory biomarkers, VOC frequency, and overall quality of life.

Methods

A PROBE (Prospective, Randomized, Open-Label, Blinded End Point) study will be conducted on individuals of any gender aged 18 years or older and diagnosed with SCD (with hemoglobin S levels more than 60% and a history of at least 1 VOC per year over the past 3 y). Individuals with acute VOC or any severe infection requiring hospitalization, a history of significant comorbidities, or hematopoietic stem cell transplantation will not be considered. The study will be conducted at the All India Institute of Medical Sciences, Bhopal, India. A total of 100 participants will undergo random assignment in a 1:1 ratio to receive either an Ayurveda regimen ( Dadimadi Ghrita , Punarnavadi Mandura , and Vasaguduchyadi Kwatha ) as an add-on to hydroxyurea or hydroxyurea alone for 8 months. The primary outcome will be a change in hemoglobin electrophoresis parameters (hemoglobin S, fetal hemoglobin, and adult hemoglobin) and the frequency of VOC episodes over 8 months. The secondary outcome measures include changes in the levels of proinflammatory markers (interleukin-6, interleukin-8, C-reactive protein, and transforming growth factor-β) and lactate dehydrogenase, frequency of hospitalization for VOCs and blood transfusions, and health-related quality of life (Short Form-8 Health Survey questionnaire). Safety will be evaluated by recording the incidence of adverse events and changes in liver and kidney function tests from baseline.

Results

The recruitment of study participants was initiated on November 1, 2023. By the second week of February 2025, 83 participants had been enrolled in the study. The final study is expected to be complete by December 31, 2025. We will start the analysis of the study outcomes in February 2026, and the publication of the final results is expected by August 2026.

Conclusions

This randomized controlled trial protocol outlines a rigorous study design aimed to explore the potential benefits of an integrated therapeutic regimen comprising Ayurveda interventions and standard conventional care in the long-term management of SCD through validated clinical and laboratory parameters. The outcomes of this study can address the needs and challenges associated with SCD management and inform future management protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellHydroxyureaMedicine, AyurvedicHumansProspective StudiesMaleRandomized Controlled Trials as TopicFemaleAdultAdolescentIndiaQuality of LifeAntisickling AgentsVaso-Occlusive CrisesYoung Adult

Stichwörter der Autor:innen

Dadimadi GhritaPunarnavadi ManduraVasaguduchyadi Kwathacomplementary medicinehydroxyureasickle cell diseasevaso-occlusive crisis

Substanzen

HydroxyureaAntisickling Agents

Autor:innen und Institutionen

  • Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy, All India Institute of Medical Sciences Bhopal, Room no 4, Ground floor, AIIMS Campus Rd, AIIMS Campus, Saket Nagar, Bhopal, Madhya Pradesh,…
  • Department of Kayachikitsa, Ayurvedic and Unani Tibbia College and Hospital, Government of National Capital Territory of Delhi, New Delhi, India.
  • Department of Medical Oncology and Hematology, All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh, India.
  • Department of Clinical Research, Central Ayurveda Research Institute, New Delhi, India.
  • Bhopal Memorial Hospital & Research Centre, Bhopal, Madhya Pradesh, India.
  • Department of Pathology and Lab Medicine, All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh, India.

ORCID-Profile: Danish Javed, Amit Kumar Rai, Sachin Bansal, Babita Yadav, Manisha Shrivastava, Garima Goel, Ashok Kumar, Sanjeev Kumar, Azeem Ahmad, Richa Singhal, Bhagwan S Sharma, Anil Mangal, Bhogavalli Chandrasekhararao, Narayanam Srikanth, Rabinarayan Acharya

Zitieren

APA

Javed, D., Rai, A. K., Bansal, S., Yadav, B., Shrivastava, M., Goel, G., Kumar, A., Kumar, S., Ahmad, A., Singhal, R., Sharma, B. S., Mangal, A., Chandrasekhararao, B., Srikanth, N., & Acharya, R. (2026). Efficacy of Ayurveda Regimen as an Adjunct to Hydroxyurea in Sickle Cell Disease: Protocol for a Prospective, Randomized, Open-Label, Blinded End Point Exploratory Study. JMIR Research Protocols. https://doi.org/10.2196/79603

Vancouver

Javed D, Rai AK, Bansal S, Yadav B, Shrivastava M, Goel G, et al. Efficacy of Ayurveda Regimen as an Adjunct to Hydroxyurea in Sickle Cell Disease: Protocol for a Prospective, Randomized, Open-Label, Blinded End Point Exploratory Study. JMIR Research Protocols. 2026. doi:10.2196/79603

BibTeX
@article{Javed2026,
  author = {Javed, Danish and Rai, Amit Kumar and Bansal, Sachin and Yadav, Babita and Shrivastava, Manisha and Goel, Garima and Kumar, Ashok and Kumar, Sanjeev and Ahmad, Azeem and Singhal, Richa and Sharma, Bhagwan S and Mangal, Anil and Chandrasekhararao, Bhogavalli and Srikanth, Narayanam and Acharya, Rabinarayan},
  title = {Efficacy of Ayurveda Regimen as an Adjunct to Hydroxyurea in Sickle Cell Disease: Protocol for a Prospective, Randomized, Open-Label, Blinded End Point Exploratory Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  doi = {10.2196/79603}
}
Kostenlos starten →